B. Yount

Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential

This study evaluates the antiviral efficacy of GS-5245 against multiple SARS-CoV-2 variants and other coronaviruses, showing broad in vitro activity and protective effects in animal models.

Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice

This study tests FDA-approved kinase inhibitors against SARS-CoV-2 in vitro and in vivo, finding that vandetanib reduces inflammatory cytokines and mitigates lung inflammation in infected mice without reducing viral load.

A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice

A broadly neutralizing antibody protects against multiple SARS-CoV and SARS-CoV-2 variants in mice by targeting a conserved epitope in the receptor-binding domain.

Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice

This study shows chimeric spike mRNA vaccines protect mice against multiple Sarbecovirus strains, including variants and zoonotic viruses, better than standard SARS-CoV-2 vaccines.

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms

This study evaluates the in vitro antiviral activity of three Ebola and Marburg virus inhibitors against SARS-CoV-2 and explores their potential mechanisms of action.

Trypsin treatment unlocks barrier for zoonotic coronaviruses infection

This study shows that proteolytic cleavage, not receptor binding, is the main barrier for two MERS-like bat coronaviruses to infect human cells, and that trypsin treatment can overcome this barrier.

Combination attenuation offers strategy for live-attenuated coronavirus vaccines

This study shows combining NSP16 mutation with other attenuating mutations creates a safe and effective live-attenuated coronavirus vaccine that works in aged mice and against heterologous challenges.